» Articles » PMID: 33012453

Locoregional Therapies for Hepatocellular Carcinoma: What Has Changed in the Past Ten Years?

Overview
Journal Clin Liver Dis
Specialty Gastroenterology
Date 2020 Oct 5
PMID 33012453
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The evolution of locoregional therapies in the last decade has been refined with improved patient selection and a development of a more personalized approach. In doing so, there has been associated improved outcomes and less toxicity. With the rapidly changing landscape of systemic therapy, the role of locoregional therapies alone or in combination for downstaging and curative intent will continue to evolve.

Citing Articles

Multidisciplinary Care and Multimodal Treatment Approaches for Unresectable Hepatocellular Carcinoma.

Lang D, Agarwal R, Brown S, Borgmann A, Lockney N, Goff L Adv Oncol. 2024; 4(1):247-262.

PMID: 38882260 PMC: 11178262. DOI: 10.1016/j.yao.2024.02.002.


Predictive Biomarkers of Immune Checkpoint Inhibitor-Based Mono- and Combination Therapies for Hepatocellular Carcinoma.

Jeng L, Wang J, Teng C J Cancer. 2024; 15(2):484-493.

PMID: 38169551 PMC: 10758026. DOI: 10.7150/jca.90128.


Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development.

Li X, Wang Y, Ye X, Liang P Front Mol Biosci. 2021; 8:635243.

PMID: 33928118 PMC: 8076864. DOI: 10.3389/fmolb.2021.635243.